EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to

Safia Chatur, Robert A Fletcher, Emily Yeung, Amanda Siriwardana, Lauren Heath, Muthiah Vaduganathan, Clare Arnott, Sunil V Badve, Sradha Kotwal, Min Jun, Meg Jardine, Carol Pollock und 3 weitere

Journal of Cardiac Failure · 2026

DOI: 10.1016/j.cardfail.2026.01.020 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Cardiac Failure, 2026. Verfasst von Safia Chatur und 14 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Canagliflozin, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Renal Insufficiency, Chronic. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Menarini Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Clinical practice guidelines recommend the initiation of sodium-glucose cotransporter 2 (SGLT2) inhibitors when the estimated glomerular filtration rate (eGFR) is ≥20 mL/min/1.73 m2. Although continuing SGLT2 inhibitors when the eGFR falls to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CanagliflozinDiabetes Mellitus, Type 2Glomerular Filtration RateRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedDisease ProgressionDouble-Blind MethodFollow-Up StudiesTreatment OutcomeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Chronic kidney diseaseSGLT-2 inhibitorscanagliflozintype 2 diabetes

Substanzen

CanagliflozinSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
  • The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia; Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia.
  • Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia; Department of Cardiology, St Vincent's Hospital, Sydney, Australia.
  • The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia; Department of Renal Medicine, St George Hospital, Sydney, Australia.

Förderung

  • Menarini Group

Zitieren

APA

Chatur, S., Fletcher, R. A., Yeung, E., Siriwardana, A., Heath, L., Vaduganathan, M., Arnott, C., Badve, S. V., Kotwal, S., Jun, M., Jardine, M., Pollock, C., Heerspink, H. J. L., Perkovic, V., & Neuen, B. L. (2026). SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2026.01.020

Vancouver

Chatur S, Fletcher RA, Yeung E, Siriwardana A, Heath L, Vaduganathan M, et al. SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to. Journal of Cardiac Failure. 2026. doi:10.1016/j.cardfail.2026.01.020

BibTeX
@article{Chatur2026,
  author = {Chatur, Safia and Fletcher, Robert A and Yeung, Emily and Siriwardana, Amanda and Heath, Lauren and Vaduganathan, Muthiah and Arnott, Clare and Badve, Sunil V and Kotwal, Sradha and Jun, Min and Jardine, Meg and Pollock, Carol and Heerspink, Hiddo J L and Perkovic, Vlado and Neuen, Brendon L},
  title = {SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to},
  journal = {Journal of Cardiac Failure},
  year = {2026},
  doi = {10.1016/j.cardfail.2026.01.020}
}
Kostenlos starten →